mumefural | 222973-44-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: mumefural
• 英文别名: 2-[2-[(5-formylfuran-2-yl)methoxy]-2-oxoethyl]-2-hydroxybutanedioic acid
• CAS: 222973-44-6
• 化学式: C₁₂H₁₂O₉
• 分子量: 300.222
• InChiKey: FYDIRKLRXHXXHY-UHFFFAOYSA-N

物化性质

• 沸点：
  590.4±50.0 °C(Predicted)
• 密度：
  1.584±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  21
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  151
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  在 溶剂黄146 作用下， 以 水 为溶剂， 反应 16.0h， 以1.1 g的产率得到mumefural
  参考文献：
  名称：

  实用合成富马酸，一种日本杏汁浓缩物

  摘要：

  描述了一种从苹果酸合成糠醛的实用的四步法。该方法的关键步骤包括将乙缩醛保护的苹果酸与溴乙酸烷基化，然后与5-（羟甲基）糠醛缩合。我们产品的某些13 C NMR数据与先前报道的有所不同，进一步的分析表明，先前报道的指配在某种程度上是错误的。

  DOI：

  10.1016/j.tet.2016.10.026

文献信息

• Citric acid derivative
  申请人：ADABIO CO., LTD.

  公开号：US11001573B2

  公开（公告）日：2021-05-11

  Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R2 represents a hydrogen atom, or R1 and R2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).

  下式（1）和（2）所代表的化合物（柠檬酸衍生物）是一种新型化合物，对肝脏疾病具有抑制作用，可用作肝脏疾病抑制剂和食品添加剂（其中 R1 代表 C1 至 C3 烷基，可选择具有羧基或羟基，R2 代表氢原子，或 R1 和 R2 可选择共同形成环状结构，代表 C2 至 C3 亚烷基链）。
• NOVEL CITRIC ACID DERIVATIVE
  申请人：ADABIO CO., LTD.

  公开号：US20200039964A1

  公开（公告）日：2020-02-06

  Compounds (citric acid derivatives) represented by formulas (1) and (2) below are novel compounds having an inhibitory effect against liver disorder and can be used as liver disorder inhibitors and food additives (wherein R 1 represents a C1 to C3 alkyl group optionally having a carboxyl group or a hydroxyl group, and R 2 represents a hydrogen atom, or R 1 and R 2 optionally form a cyclic structure together to represent a C2 to C3 alkylene chain).
• COMPOSITIONS FOR PREVENTING OR TREATING COGNITIVE IMPAIRMENT-RELATED DISEASE COMPRISING MUMEFURAL
  申请人：KOREA INSTITUTE OF ORIENTAL MEDICINE

  公开号：US20210106550A1

  公开（公告）日：2021-04-15

  The present invention relates to a composition for preventing or treating a cognitive impairment-related disease, which includes mumefural, and more particularly, to a pharmaceutical composition; a health functional food composition; and a feed composition respectively for preventing or treating a cognitive impairment-related disease; a health functional food composition for enhancing learning ability, cognitive function, or memory, each composition including mumefural or an acceptable salt thereof as an active ingredient; and a method of treating a cognitive impairment-related disease using the pharmaceutical composition. Due to excellent effects of the mumefural of the present invention on normalizing damage to the brain (i.e., basal forebrain, white matter, hippocampus, etc.) and excellent effects thereof on enhancing memory, the mumefural of the present invention may be effectively used to treat neurodegenerative diseases (i.e., dementia, Alzheimer's disease, etc.) and cognitive impairment caused by brain damage (i.e., memory impairment), and may be used to enhance learning ability, cognitive function, and memory.